AR034588A1 - Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos - Google Patents
Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentosInfo
- Publication number
- AR034588A1 AR034588A1 ARP020101443A ARP020101443A AR034588A1 AR 034588 A1 AR034588 A1 AR 034588A1 AR P020101443 A ARP020101443 A AR P020101443A AR P020101443 A ARP020101443 A AR P020101443A AR 034588 A1 AR034588 A1 AR 034588A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- derivatives
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol, que comprenden un compuesto de fórmula (1) en donde: W es SO2, CO, CONH, CSNH ó (CH2)x; X es O, SOy, ó NR13; Y es CR14 ó N; Z es CR15 ó N, con la condición que cuando Y es N, entonces Z debe ser CR15; m y x son cada uno independientemente 0 ó un entero de 1, 2 ó 3; n y p son cada uno independientemente un entero de 1, 2 ó 3; R1 es halógeno, CN, OR16, CO2R17, CONR18R19, CNR20R21R22, SO2NR23R24, SOwR25, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, fenilo o un grupo heteroarilo, cada uno opcionalmente sustituido; R2, R3, R5, R6, R7, R8, R9, R10 y R11 son cada uno independientemente H o un grupo alquilo C1-6 opcionalmente sustituido; R4 es H, CNR26NR27R28, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R12 es un grupo arilo, heteroarilo o alquilo C1-6 opcionalmente sustituido; w e y son cada uno 0 ó un entero de 1 ó 2; R13 es H, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R14 y R15 son cada uno de manera independiente H, halógeno, o un grupo alquilo C1-6, arilo, heteroarilo o alcoxi C1-6, cada uno opcionalmente sustituido; R16 es H, COR29, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R17 y R29 son cada uno de manera independiente H, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R18, R19, R20, R21, R22, R26, R27 y R28 son cada uno de manera independiente H, o un grupo alquilo C1-6 opcionalmente sustituido; R23 y R24 son cada uno de manera independiente H, o un grupo alquilo C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; y R25 es un grupo arilo, heteroarilo o alquilo C1-6 opcionalmente sustituidos; o los estereoisómeros del mismo o las sales farmacéuticamente aceptables del mismo; un proceso para su preparación, intermediarios, composiciones farmacéuticas y el uso de dichos derivados para la manufactura de medicamentos, para el tratamiento terapéutico de trastornos relacionados con el sistema nervioso central o afectados por el receptor de 5-HT6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28564401P | 2001-04-20 | 2001-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034588A1 true AR034588A1 (es) | 2004-03-03 |
Family
ID=23095117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101443A AR034588A1 (es) | 2001-04-20 | 2002-04-19 | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6831094B2 (es) |
| EP (1) | EP1392682A2 (es) |
| JP (1) | JP2004526781A (es) |
| KR (1) | KR20030088507A (es) |
| CN (1) | CN1293073C (es) |
| AR (1) | AR034588A1 (es) |
| AU (1) | AU2002309585B2 (es) |
| BR (1) | BR0209047A (es) |
| CA (1) | CA2444036A1 (es) |
| EA (1) | EA200301143A1 (es) |
| HU (1) | HUP0303801A2 (es) |
| IL (1) | IL158448A0 (es) |
| MX (1) | MXPA03009490A (es) |
| NO (1) | NO20034647L (es) |
| PL (1) | PL366639A1 (es) |
| WO (1) | WO2002085853A2 (es) |
| ZA (1) | ZA200309009B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513809A1 (en) | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| RU2350602C2 (ru) * | 2002-12-03 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| CN101291913A (zh) * | 2005-08-15 | 2008-10-22 | 惠氏公司 | 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物 |
| CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
| JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体 |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| EP2029550A2 (en) * | 2006-06-01 | 2009-03-04 | Wyeth a Corporation of the State of Delaware | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
| WO2009006267A2 (en) * | 2007-06-28 | 2009-01-08 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
| WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
| ME02663B (me) | 2010-10-06 | 2017-06-20 | Glaxosmithkline Llc | Derivati benzimidazola kao inhibitori pi3 kinaze |
| CN104725295B (zh) | 2013-12-20 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| SG11201610407QA (en) | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| UA125318C2 (uk) | 2017-08-01 | 2022-02-16 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Піразоло- і триазолобіциклічні сполуки як інгібітори jak-кінази |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| US5274097A (en) * | 1988-04-19 | 1993-12-28 | Bayer Aktiengesellschaft | 1,3-disubstituted pyrrolidines |
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| TW288010B (es) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| WO1995003298A1 (en) | 1993-07-19 | 1995-02-02 | Fujisawa Pharmaceutical Co., Ltd. | BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| JPH0940646A (ja) | 1995-07-27 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | ベンゼン縮合環誘導体又はその塩 |
| GB9523462D0 (en) | 1995-11-16 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| CA2378047A1 (en) | 1999-07-15 | 2001-01-25 | Methvin Isaac | Heterocyclic compounds for the treatment of migraine |
| CA2432654A1 (en) * | 2000-12-22 | 2002-07-04 | Wyeth | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
-
2002
- 2002-04-19 HU HU0303801A patent/HUP0303801A2/hu unknown
- 2002-04-19 US US10/126,805 patent/US6831094B2/en not_active Expired - Fee Related
- 2002-04-19 CN CNB028123409A patent/CN1293073C/zh not_active Expired - Fee Related
- 2002-04-19 PL PL02366639A patent/PL366639A1/xx unknown
- 2002-04-19 CA CA002444036A patent/CA2444036A1/en not_active Abandoned
- 2002-04-19 EA EA200301143A patent/EA200301143A1/ru unknown
- 2002-04-19 EP EP02736592A patent/EP1392682A2/en not_active Withdrawn
- 2002-04-19 JP JP2002583380A patent/JP2004526781A/ja active Pending
- 2002-04-19 MX MXPA03009490A patent/MXPA03009490A/es active IP Right Grant
- 2002-04-19 AU AU2002309585A patent/AU2002309585B2/en not_active Expired - Fee Related
- 2002-04-19 IL IL15844802A patent/IL158448A0/xx unknown
- 2002-04-19 WO PCT/US2002/012512 patent/WO2002085853A2/en active Application Filing
- 2002-04-19 AR ARP020101443A patent/AR034588A1/es not_active Application Discontinuation
- 2002-04-19 KR KR10-2003-7013584A patent/KR20030088507A/ko not_active Application Discontinuation
- 2002-04-19 BR BR0209047-3A patent/BR0209047A/pt not_active IP Right Cessation
-
2003
- 2003-10-17 NO NO20034647A patent/NO20034647L/no not_active Application Discontinuation
- 2003-11-19 ZA ZA200309009A patent/ZA200309009B/en unknown
-
2004
- 2004-09-24 US US10/949,061 patent/US20050065185A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303801A2 (hu) | 2004-03-01 |
| AU2002309585B2 (en) | 2008-01-31 |
| CN1518548A (zh) | 2004-08-04 |
| PL366639A1 (en) | 2005-02-07 |
| US20050065185A1 (en) | 2005-03-24 |
| WO2002085853A3 (en) | 2002-12-19 |
| CN1293073C (zh) | 2007-01-03 |
| EP1392682A2 (en) | 2004-03-03 |
| BR0209047A (pt) | 2004-08-10 |
| JP2004526781A (ja) | 2004-09-02 |
| IL158448A0 (en) | 2004-05-12 |
| ZA200309009B (en) | 2005-02-21 |
| EA200301143A1 (ru) | 2004-02-26 |
| CA2444036A1 (en) | 2002-10-31 |
| NO20034647L (no) | 2003-11-20 |
| MXPA03009490A (es) | 2004-02-12 |
| NO20034647D0 (no) | 2003-10-17 |
| WO2002085853A2 (en) | 2002-10-31 |
| US6831094B2 (en) | 2004-12-14 |
| US20030078286A1 (en) | 2003-04-24 |
| KR20030088507A (ko) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR034588A1 (es) | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR031248A1 (es) | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR035669A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones que las comprenden, y usos de dichos compuestos en la preparacion de medicamentos | |
| UY27368A1 (es) | Nuevos compuestos | |
| NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
| NO20055977L (no) | Nye benzimidazolderivater | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| NO20062370L (no) | Amidderivater | |
| AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |